Limaryl M 2 mg+500 mg (Tablet (Extended Release))

Unit Price: ৳ 12.00 (3 x 10: ৳ 360.00)

Strip Price: ৳ 120.00

Medicine Details

Category	Details
Generic	Glimepiride metformin
Company	Popular pharmaceuticals ltd
Also available as	Limaryl m 1 mg tablet

Adjunct to diet and exercise in type 2 diabetes mellitus patients
Monotherapy with glimepiride or metformin not resulting in adequate glycemic control
Replacement of combination therapy of glimepiride and metformin

Decreases blood glucose concentration
Stimulates release of insulin from functioning pancreatic beta cells
Improves sensitivity of beta cells to glucose stimulus
Reduces basal hepatic glucose production
Increases peripheral tissue sensitivity to insulin
Improves insulin sensitivity by increasing peripheral glucose uptake and utilization
Lowers both basal and postprandial plasma glucose
Does not produce hypoglycemia
Decreases hepatic glucose production
Decreases intestinal absorption of glucose

Governed by desired blood glucose level
Must be the lowest sufficient to achieve desired metabolic control
Regular measurement of glucose levels in blood and urine
Avoid correcting mistakes by taking larger dose
Timely dose reduction or cessation to avoid hypoglycemia
The highest recommended dose per day should be 8 mg of glimepiride and 2000 mg of metformin
Starting dose should not exceed the daily doses of glimepiride or metformin already being taken
When switching from combination therapy, administer on basis of current dosage

Metabolized by CYP2C9
Potentiation and hypoglycemia with drugs like insulin, oral antidiabetics, ACE inhibitors, anabolic steroids
Weakening and raised blood glucose levels with drugs like barbiturates, corticosteroids, diuretics
H2 receptor antagonists, beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of blood-glucose-lowering effect
Alcohol intake may potentiate or weaken blood-glucose-lowering action in an unpredictable fashion

Hypersensitivity to glimepiride, metformin, sulfonamides, or any excipients
In pregnant and breastfeeding women
Severe impairment of liver function and in dialysis patients
Acute metabolic acidosis, severe renal failure, acute conditions altering renal function, hepatic insufficiency, acute alcohol intoxication, lactation

Hypoglycemia, prolonged hypoglycemia, visual impairment, gastrointestinal symptoms, hepatitis, dysgeusia, changes in blood picture, alopecia, allergic reactions, weight gain
Gastrointestinal symptoms, metallic taste, decrease of vitamin B12 absorption, lactic acidosis, hemolytic anemia, reduction of thyrotropin level, hypomagnesemia

Glimepiride must not be taken during pregnancy, patients should change over to insulin
Metformin should not be used in pregnancy, diabetes should be treated with insulin to maintain blood glucose levels as close to normal as possible
Glimepiride must not be taken by breastfeeding women, patients must change over to insulin
Metformin is excreted into milk in lactating rats, a decision should be made whether to discontinue nursing or discontinue metformin

Initial weeks of treatment may increase risk of hypoglycemia, especially when illness occurs or lifestyle changes
Regular monitoring of thyroid-stimulating hormone (TSH) levels is recommended in patients with hypothyroidism
Long-term treatment associated with decrease in vitamin B12 serum levels leading to peripheral neuropathy

Insufficient data to recommend pediatric use
Assessment of GFR before initiation of treatment
Renal function assessment in patients at increased risk, especially in the elderly
Maximum daily dose based on GFR levels